The ‘Pinking’ of Viagra Culture: Drug Industry Efforts to Create and Repackage Sex Drugs for Women

This essay will describe how the success of Viagra stimulated drug companies to create a women's sexual condition comparable to erectile problems in men for which they could market new sex drugs to women. The heart of the article focuses on two interrelated aspects of Viagra culture playing out in drug industry efforts to create and expand a market for sex drugs for women: (1) the industry's ‘Hunt for the Pink Viagra’ to treat the ‘disease’ of female sexual dysfunction (FSD), and (2) the prescription and promotion of off-label uses of men's sex drugs to women. In order to contextualize these two trends, the article outlines key activities and actions that have enabled the drug industry to consolidate power and build capacity in this area, including: mass dissemination of estimates of disease prevalence; the institutionalization of FSD in academic circles, which includes strategic revision of disease definitions as well as the creation of a legitimized infrastructure for dissemination of supporting research and education; and public-relations stimulated mainstream media coverage. The article concludes with a consideration of the ongoing challenges to the medicalization of women's sexuality as well as to harmful corporate practices more broadly.

[1]  A. Relman,et al.  Separating continuing medical education from pharmaceutical marketing. , 2001, JAMA.

[2]  H. Hartley.  Promising Liberation but Delivering Business as Usual? , 2002 .

[3]  S. Davis,et al.  Circulating Androgen Levels and Self-Reported Sexual Function in Women , 2005, Journal of the American Medical Association (JAMA).

[4]  M Angell.  Is academic medicine for sale? , 2000, The New England journal of medicine.

[5]  H. Hartley.  “BIG PHARMA” IN OUR BEDROOMS: AN ANALYSIS OF THE MEDICALIZATION OF WOMEN’S SEXUAL PROBLEMS , 2003 .

[6]  J. Fishman,et al.  Manufacturing Desire: , 2004, Social Studies of Science.

[7]  Meika Loe,et al.  The Rise of Viagra: How the Little Blue Pill Changed Sex in America , 2004 .

[8]  E. Laumann,et al.  Sexual dysfunction in the United States: prevalence and predictors. , 1999, JAMA.

[9]  Marcia Angell,et al.  The Truth About the Drug Companies , 2004 .

[10]  L. Tiefer.  Sexology and the pharmaceutical industry: The threat of co‐optation , 2000 .

[11]  N. Freudenberg.  Public Health Advocacy to Change Corporate Practices: Implications for Health Education Practice and Research , 2005, Health education & behavior : the official publication of the Society for Public Health Education.

[12]  Let's Talk About Sex--and Drugs , 2005, Science.

[13]  J. Kassirer.  On the Take , 2005 .

[14]  J. Bancroft.  The Medicalization of Female Sexual Dysfunction: The Need for Caution , 2002, Archives of sexual behavior.

[15]  L. Derogatis,et al.  Report of the international consensus development conference on female sexual dysfunction: definitions and classifications. , 2000, The Journal of urology.

[16]  R. Moynihan.  The marketing of a disease: female sexual dysfunction , 2003, BMJ : British Medical Journal.

[17]  J. S. Long,et al.  Distress About Sex: A National Survey of Women in Heterosexual Relationships , 2003, Archives of sexual behavior.

[18]  L. Tiefer,et al.  The "Consensus" Conference on Female Sexual Dysfunction: Conflicts of Interest and Hidden Agendas , 2001, Journal of sex & marital therapy.

[19]  L. Tiefer,et al.  Taking a Biological Turn: The Push for a "Female Viagra" and the Medicalization of Women's Sexual Problems , 2003 .

[20]  P. Conrad,et al.  Medicalization, markets and consumers. , 2004, Journal of health and social behavior.

[21]  T. Bodenheimer,et al.  Uneasy alliance--clinical investigators and the pharmaceutical industry. , 2000, The New England journal of medicine.

[22]  M. Angell.  The pharmaceutical industry--to whom is it accountable? , 2000, The New England journal of medicine.

[23]  J. Abramson.  Overdosed America: The Broken Promise of American Medicine , 2004 .

[24]  Valéria Cavalcanti Rolla,et al.  On the Take: How Medicine's Complicity with Big Business Can Endanger Your Health , 2004 .